الفهرس | Only 14 pages are availabe for public view |
Abstract Narrow Therapeutic Index (NTI) medications represent a major problem for clinicians, pharmacists and patients. Significant variability in quality and efficacy commonly exist upon switching across generic NTI products compared to their brands and even within brand products themselves. (1) Numerous studies have shown differences in the bioequivalence and clinical performance between several NTI generics and/or NTI multi-source brand products, such as Carbamazepine (Tegretol®), Phenytoin (Epanutin®), Thyroxine (Eltroxin®) and Warfarin (Marevan®). However, this problem has been marginalized in pharmaceutical research field for several decades, which consequently augments the need for comparing and evaluating the pharmaceutical quality, stability and efficacy of generics and/or brand products marketed under the same brand name or manufactured in different countries under its own licensing trademark™. (2) Market surveys have shown that Egypt is one of the countries suffering from this problem (Table1). |